Jonathan Haigh, Head of UK Sites, FUJIFILM Biotechnologies, explores how advanced technologies are being used to reduce risk and strengthen global supply chains for biologics.
Biologics development carries inherent risk, particularly in early phases where funding constraints make speed, cost reduction, and efficient process development critical. High-throughput experimentation, automation, and AI-driven tools are increasingly being applied to bioreactor monitoring, inline analytics, and experimental design to enable faster development while supporting scalable, quality-by-design processes. Jonathan Haigh, Head of UK Sites, FUJIFILM Biotechnologies, discusses how harmonized manufacturing facilities and end-to-end digitization are further reducing supply chain risk and enabling agile, global commercial manufacturing.
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
